0
Abstract: Poster Presentations |

Effect of Cilomilast on Quality of Life Improvement/Deterioration and Non-drug Costs in Patients With Chronic Obstructive Pulmonary Disease FREE TO VIEW

Rohit D. Borker, PhD; Andrea Morris, RN; Junghee Lim, PhD; Jin Zhu, PhD; Colin Reisner, MD
Author and Funding Information

GlaxoSmithKline, Research Triangle Park, NC


Chest


Chest. 2003;124(4_MeetingAbstracts):170S-b-171S. doi:10.1378/chest.124.4_MeetingAbstracts.170S-b
Text Size: A A A
Published online

Abstract

PURPOSE:  The present analyses was performed to estimate the effect of cilomilast on chronic obstructive pulmonary disease (COPD) patients’ relative risk (RR) of improvement/deterioration in quality of life (QOL) and non-drug medical costs.METHOD: The analyses was based on a randomized, double blind, placebo-controlled study, which evaluated cilomilast (15 mg twice daily) in patients with COPD. Patients’ QOL was measured using the St. George’s Respiratory Questionnaire (SGRQ), a disease-specific QOL questionnaire. The RR estimates for QOL improvement/deterioration were determined based on study results. The healthcare utilization data on physician office visits, emergency department visits, and hospitalizations were collected during the trial.

RESULTS:  A total of 536 patients (cilomilast = 340, placebo = 196) were included in the analyses. A greater proportion of patients achieved a clinically meaningful QOL improvement in the cilomilast group as compared to placebo (47.6% vs. 31.6%, respectively) resulting in a significant RR of QOL improvement of 1.51 (95% CI: 1.21 to 1.88). A greater proportion of patients experienced clinically relevant deterioration in their QOL in the placebo group as compared to cilomilast (39.3% vs. 22.9%, respectively) resulting in a significant RR of QOL deterioration of 0.58 (95% CI: 0.45 to 0.76). Moreover, the non-drug medical cost per patient for the 24-week treatment period was significantly lower in the cilomilast group ($12.06, 95% CI: $3.85 to $27.89) as compared to placebo group ($97.79, 95% CI: $35.37 to $176.24).CONCLUSIONS: Patients in cilomilast group were 1.5 times more likely to experience a clinically meaningful improvement in their QOL and about 40 % less likely to experience a clinically relevant deterioration in their QOL as compared placebo. Patients in the cilomilast group also experienced significant cost reductions in terms of their non-drug medical costs as compared to placebo.

CLINICAL IMPLICATIONS:  COPD patients on cilomilast are more likely to experience QOL improvement and less likely to experience QOL deterioration at significantly lower non-drug medical costs as compared to placebo.

DISCLOSURE:  R.D. Borker, Employee - GlaxoSmithKline, Industry.

Wednesday, October 29, 2003

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543